Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.30 |
| ▸ | CA2 | P00918 | 4/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiocyanic Acid SCHEMBL643812 | 0.94 | — | — | |
| Thiocyanic Acid SCHEMBL11270674 | 0.86 | CA1 (0.30) | CA1CA2CA5ACA9CA5B | |
| Thiocyanic Acid SCHEMBL3862606 | 0.86 | CA1 (0.30) | CA1CA2CA5ACA9CA5B | |
| Thiocyanic Acid SCHEMBL6232486 | 0.86 | CA1 (0.30) | CA1CA2CA5ACA9CA5B | |
| Thiocyanic Acid SCHEMBL21410334 | 0.86 | — | — | |
| Thiocyanic Acid SCHEMBL5146104 | 0.86 | CA1 (0.30) | CA1CA2CA5ACA9CA5B | |
| Thiocyanic Acid SCHEMBL42005 | 0.86 | CA1 (0.30) | CA1CA2CA5ACA9CA5B | |
| Thiocyanic Acid SCHEMBL4504379 | 0.86 | CA1 (0.30) | CA1CA2CA5ACA9CA5B | |
| Thiocyanic Acid SCHEMBL11509407 | 0.86 | — | — | |
| Thiocyanic Acid SCHEMBL21177322 | 0.86 | TSHR (0.31) | CA1CA2CA5ACA9CA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562928-B1 | Pharmaceutical composition containing a cisplatin and platinum thiocyanate combination | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2020-02-18 | — | — | US | disclosed |
| EP-0440611-A1 | INTENSIFICATION OF POLYMERISED CHROMOGENS IN IMMUNOCHEMICAL ANALYSIS | University of Wales College of Medicine (GB) | 1991-08-14 | — | — | EP | disclosed |
| WO-1989006362-A1 | INTENSIFICATION OF POLYMERISED CHROMOGENS IN IMMUNOCHEMICAL ANALYSIS | UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562928-B1 | Pharmaceutical composition containing a cisplatin and platinum thiocyanate combination | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ERCC5, PKD1 | CA1 162/4885CA2 172/4885CA5A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.